Showing results (431-440 of 566) with videos related to

Sort By:
Pageof 57
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 28, 2019
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasisRichard G B Langley, Kristian Reich, Vibeke Strand, et al.
The Journal of Rheumatology. Supplement|June 3, 2020
The GRAPPA-OMERACT Working Group: 4 Prioritized Domains for Completing the Core Outcome Measurement Set for Psoriatic Arthritis 2019 UpdatesYing Ying Leung, William Tillett, Ana-Maria Orbai, et al.
The Journal of Rheumatology|August 3, 2011
Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare WorkshopClifton O Bingham, Rieke Alten, Susan J Bartlett, et al.
The Journal of Rheumatology|November 3, 2005
Fibromyalgia syndromePhilip J Mease, Daniel J Clauw, Lesley M Arnold, et al.
BMJ Open|March 5, 2025
Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)Michael E Weinblatt, Peter C Taylor, Iain B McInnes, et al.
Annals of the Rheumatic Diseases|June 24, 2021
Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patientsKaterina Chavatza, Myrto Kostopoulou, Dionysis Nikolopoulos, et al.
Zeitschrift Fur Rheumatologie|April 3, 2024
[Current data on rheumatological care: annual report from the National database (NDB) of the regional collaborative arthritis centres in Germany]Katinka Albrecht, Katja Thiele, Tobias Alexander, et al.
The Journal of Rheumatology|March 3, 2019
Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid ArthritisMaria A Lopez-Olivo, José B Negrón, Richard J Zogala, et al.
Arthritis and Rheumatism|November 1, 2006
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis studyClifton O Bingham, J Chris Buckland-Wright, Patrick Garnero, et al.
The Journal of Rheumatology|February 17, 2019
Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT MethodologyLara J Maxwell, Dorcas E Beaton, Beverley J Shea, et al.
Pageof 57